SLC1A2 and Parkinson disease: In a recent study, EAAT2 was validated as a therapeutic target for PD through analyses showing that knocking down its expression in astrocytes led to an increase in reactive astrocytes, progressive motor deficits, and nigral DA neuronal death in a mouse model of PD [52].